{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:39:14Z","timestamp":1715981954120},"reference-count":11,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.eururo.2007.05.010","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T03:45:12Z","timestamp":1179978312000},"page":"1300-1302","source":"Crossref","is-referenced-by-count":7,"title":["What is the Optimal BCG Dose in Non\u2013Muscle-Invasive Bladder Cancer?"],"prefix":"10.1016","volume":"52","author":[{"given":"J. Alfred","family":"Witjes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2007.05.010_bib1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.05.010_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000281694","article-title":"The use of intravesical BCG in superficial bladder tumors. An overview","volume":"45","author":"Witjes","year":"1990","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2007.05.010_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","article-title":"Intravesical instillation therapy with bacillus Calmette-Gu\u00e9rin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"14","author":"Shintani","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2007.05.010_bib4","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Gu\u00e9rin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2007.05.010_bib5","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0959-8049(93)90102-L","article-title":"A randomized prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Intravesical instillations in superficial bladder cancer","volume":"29A","author":"Witjes","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2007.05.010_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1569-9056(07)60152-3","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) used for intravesical instillations in the treatment of nonmuscle invasive transitional cell carcinoma (TCC) of the bladder: does the strain matter","volume":"6","author":"Thalmann","year":"2007","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2007.05.010_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette-Gu\u00e9rin: a prospective randomized study in patients with recurrent superficial bladder tumors","volume":"155","author":"Luftenegger","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.05.010_bib8","first-page":"1","article-title":"Guidelines on TaT1 (non-muscle invasive) bladder cancer","author":"Oosterlinck","year":"2007","journal-title":"EAU Guidelines"},{"key":"10.1016\/j.eururo.2007.05.010_bib9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.05.010_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","article-title":"A low dose bacillus Calmette-Gu\u00e9rin regimen in superficial bladder cancer therapy: is it effective?","volume":"146","author":"Pagano","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.05.010_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0210-4806(99)72366-1","article-title":"Our experience with 1mg BCG vaccine instillation in T1 stage cancer of the bladder","volume":"23","author":"Rivera","year":"1999","journal-title":"Actas Urol Esp"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807007117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807007117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,28]],"date-time":"2019-04-28T04:03:04Z","timestamp":1556424184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283807007117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0302283807007117"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2007.05.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}